Epclusa (sofosbuvir/velpatasvir tablets and oral pellets – Gilead) — Cigna

Initial criteria

• Approve for an indication or condition addressed as an approval in the Recommended Authorization Criteria section (FDA-Approved Indications or Other Uses with Supportive Evidence)
• Approve the duration described above to complete a course therapy (e.g., a patient who should receive 12 weeks, and has received 3 weeks, should be approved for 9 weeks to complete their 12-week course)

Approval duration

up to full course (remaining weeks of therapy)